Skip to main content
OpenTrials
Completed

NCT Number: NCT03379571

Competing Risk of Death and ESRD in Incident CKD Patients

Although chronic kidney disease (CKD) affects a growing number of people, epidemiologic data on incident CKD in the general population are scarce. Screening strategies to increase early CKD detection have been developed.

Methods: From a community-based sample of 4,409 individuals residing in a well-defined geographical area, investigators determined the number of patients having a first serum creatinine value ≥1.7 mg/dL and present for at least 3 months that allowed us to calculate an annual incidence rate of CKD (stages 3 to 5). CKD (stages 3 to 5) was defined by estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Investigators also described the primary care, outcomes and risk factors associated with outcomes using competing risks analyses for these CKD patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Kidney Diseases Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >= 18 years
  • first serum creatinine value ≥1.7 mg/dL reached after January 1st, 2004
  • and present for at least 3 months
  • residing in the given geographical area (the Urban Community of Greater Nancy (UCGN))

Exclusion criteria

  • <18 years
  • prevalent CKD patient : CKD diagnosis before January 1st, 2004
  • patients on dialysis or renal transplanted
  • refusal of participation

Treatment and study plan

Primary outcomes

  1. annual incidence rate of CKD

    Time frame: inclusion

    number of patients residing in a well-defined geographical area having a first serum creatinine value ≥1.7 mg/dL after January 1st, 2004 and still present for at least 3 months

Secondary outcomes

  1. dialysis initiation

    Time frame: through study completion, 6 year after study start

    number of dialysis initiation.

  2. death

    Time frame: through study completion, 6 year after study start

    number of death

  3. management of CKD patients

    Time frame: through study completion, 6 year after study start

    %patients referred to a nephrologist, decline of the renal function

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Competing Risk of Death and End-stage Renal Disease in Incident Chronic Kidney Disease (Stages 3 to 5): the EPIRAN Community-based Study

Acronym: EPIRAN

Important dates

Study start
2004
Primary completion
2009
Study completion
2009
First posted
Dec 20, 2017
Registry last updated
Dec 20, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.